Furthermore, a classification of tumor reactivity and bystander CD8+ TILs in treatment-naïve primary CRC patients, based on the expression of CD39 and CD103, indicated that DNA methylation plays a significant role in both tumor reactivity and the formation of bystander CD8+ TILs [21]. The gene discussed is ENTPD1; the disease is neoplasm.